New PAH drug IKT-001 moves to Long-Term safety check
NCT ID NCT07632898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is checking the long-term safety of a daily pill called IKT-001 for people with pulmonary arterial hypertension (PAH), a serious lung condition. About 484 adults who have already completed an earlier IKT-001 study will take the drug for an extended period. Researchers will track side effects and also measure how far patients can walk in 6 minutes and a heart stress marker in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IKT-001 (tablet taken by mouth once daily)
What this could lead to
If successful, this could confirm that IKT-001 is safe enough for long-term use in managing pulmonary arterial hypertension.
What could go wrong
This is an open-label extension study with no placebo group, so results may be less reliable. It only includes people who tolerated IKT-001 before, which may not reflect the broader patient population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••